SG11202011170YA - Antibodies against lif and dosage forms thereof - Google Patents
Antibodies against lif and dosage forms thereofInfo
- Publication number
- SG11202011170YA SG11202011170YA SG11202011170YA SG11202011170YA SG11202011170YA SG 11202011170Y A SG11202011170Y A SG 11202011170YA SG 11202011170Y A SG11202011170Y A SG 11202011170YA SG 11202011170Y A SG11202011170Y A SG 11202011170YA SG 11202011170Y A SG11202011170Y A SG 11202011170YA
- Authority
- SG
- Singapore
- Prior art keywords
- dosage forms
- antibodies against
- against lif
- lif
- antibodies
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382327 | 2018-05-14 | ||
| EP18382359 | 2018-05-25 | ||
| EP19382208 | 2019-03-26 | ||
| EP19382331 | 2019-05-03 | ||
| PCT/IB2019/000541 WO2019220204A2 (en) | 2018-05-14 | 2019-05-13 | Antibodies against lif and dosage forms thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202011170YA true SG11202011170YA (en) | 2020-12-30 |
Family
ID=67902550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202011170YA SG11202011170YA (en) | 2018-05-14 | 2019-05-13 | Antibodies against lif and dosage forms thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220064279A1 (en) |
| EP (1) | EP3794031A2 (en) |
| JP (1) | JP7536654B2 (en) |
| KR (1) | KR20210008514A (en) |
| CN (1) | CN112638941A (en) |
| AU (1) | AU2019269131B2 (en) |
| CA (1) | CA3099406A1 (en) |
| MA (1) | MA52021A (en) |
| SG (1) | SG11202011170YA (en) |
| WO (1) | WO2019220204A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7379390B2 (en) * | 2018-06-18 | 2023-11-14 | メドイミューン・リミテッド | Combination of LIF inhibitor and platinum-based antineoplastic agent for use in cancer treatment |
| JP7266108B2 (en) | 2019-02-18 | 2023-04-27 | イーライ リリー アンド カンパニー | therapeutic antibody formulation |
| JP2023504642A (en) * | 2019-12-04 | 2023-02-06 | メドイミューン・リミテッド | Antibodies against LIF and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| KR20060067983A (en) | 1999-01-15 | 2006-06-20 | 제넨테크, 인크. | Polypeptide variants with altered effector function |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| ES2363358B1 (en) | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | THERAPEUTIC AGENTS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AN INDESEABLE CELLULAR PROLIFERATION. |
| EP2371860A1 (en) | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| AU2015314980A1 (en) * | 2014-09-10 | 2017-03-02 | The Regents Of The University Of California | Targeting K-Ras-mediated signaling pathways and malignancy by anti-hLIF antibodies |
| CN107074954A (en) | 2014-10-21 | 2017-08-18 | 埃博灵克斯股份有限公司 | The treatment of IL 6R relevant diseases |
| EP3173483A1 (en) * | 2015-11-27 | 2017-05-31 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Agents for the treatment of diseases associated with undesired cell proliferation |
| US10583191B2 (en) * | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
| MA52231A (en) * | 2018-04-12 | 2021-02-17 | Fundacio Privada Inst Catalana De Recerca I Estudis Avancats | COMBINATION OF LIF INHIBITORS AND PD-1 AXIS INHIBITORS FOR USE IN THE TREATMENT OF CANCER |
-
2019
- 2019-05-13 EP EP19765782.8A patent/EP3794031A2/en active Pending
- 2019-05-13 CN CN201980046565.4A patent/CN112638941A/en active Pending
- 2019-05-13 KR KR1020207035617A patent/KR20210008514A/en unknown
- 2019-05-13 SG SG11202011170YA patent/SG11202011170YA/en unknown
- 2019-05-13 WO PCT/IB2019/000541 patent/WO2019220204A2/en unknown
- 2019-05-13 JP JP2020563980A patent/JP7536654B2/en active Active
- 2019-05-13 CA CA3099406A patent/CA3099406A1/en active Pending
- 2019-05-13 US US17/055,279 patent/US20220064279A1/en active Pending
- 2019-05-13 MA MA052021A patent/MA52021A/en unknown
- 2019-05-13 AU AU2019269131A patent/AU2019269131B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019269131A1 (en) | 2021-01-07 |
| CN112638941A (en) | 2021-04-09 |
| KR20210008514A (en) | 2021-01-22 |
| CA3099406A1 (en) | 2019-11-21 |
| AU2019269131B2 (en) | 2024-02-22 |
| EP3794031A2 (en) | 2021-03-24 |
| JP7536654B2 (en) | 2024-08-20 |
| US20220064279A1 (en) | 2022-03-03 |
| WO2019220204A3 (en) | 2019-12-26 |
| WO2019220204A2 (en) | 2019-11-21 |
| JP2021523906A (en) | 2021-09-09 |
| MA52021A (en) | 2021-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276950A (en) | Anti-cd73 antibodies and uses thereof | |
| IL275737A (en) | Antibodies and variants thereof against tigit | |
| IL282968A (en) | Anti-nkg2a antibodies and uses thereof | |
| ZA202006904B (en) | Anti-il-4r antibody and use thereof | |
| SG11202100746WA (en) | Anti-tigit antibody and use thereof | |
| ZA202006066B (en) | Anti-hla-g antibodies and use thereof | |
| SG11202105885WA (en) | Anti-claudin antibodies and uses thereof | |
| SG11202104240TA (en) | Cll1-targeting antibody and application thereof | |
| IL277559A (en) | Multispecific antibodies and use thereof | |
| IL275826A (en) | Anti-mct1 antibodies and uses thereof | |
| SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
| IL281297A (en) | Anti-npr1 antibodies and uses thereof | |
| SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
| IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
| IL277330A (en) | Anti-il-27 antibodies and uses thereof | |
| IL282708A (en) | Anti-tim-3 antibodies and their use | |
| IL281202A (en) | Anti-tnfrsf9 antibodies and uses thereof | |
| IL280321A (en) | Anti-cxcr2 antibodies and uses thereof | |
| IL282707A (en) | Anti-tim-3 antibodies and their use | |
| IL287690A (en) | Anti-hvem antibodies and use thereof | |
| SG11202012680TA (en) | Anti-l1cam antibodies and uses thereof | |
| IL277075A (en) | Anti-phf-tau antibodies and uses thereof | |
| IL276548A (en) | Bcma-binding antibodies and uses thereof | |
| IL283926A (en) | Anti-alpha-synuclein antibodies and uses thereof | |
| SG11202011170YA (en) | Antibodies against lif and dosage forms thereof |